docetaxel anhydrous has been researched along with Insulin Resistance in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fan, J; Ling, R; Wang, L; Yan, CY; Yun, J | 1 |
1 other study(ies) available for docetaxel anhydrous and Insulin Resistance
| Article | Year |
|---|---|
Activation of hypoxia-inducible factor-1α by prolonged in vivo hyperinsulinemia treatment potentiates cancerous progression in estrogen receptor-positive breast cancer cells.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Humans; Hyperinsulinism; Hypoxia-Inducible Factor 1, alpha Subunit; Insulin; Insulin Resistance; MCF-7 Cells; Mice; Mice, Inbred BALB C; Mice, Nude; Reactive Oxygen Species; Receptors, Estrogen; Signal Transduction; Taxoids; Ubiquitination; Xenograft Model Antitumor Assays | 2017 |